Clinical Trials Logo

First Episode Schizophrenia clinical trials

View clinical trials related to First Episode Schizophrenia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03784222 Terminated - Clinical trials for First Episode Schizophrenia

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

Start date: January 22, 2019
Phase: Phase 4
Study type: Interventional

This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients

NCT ID: NCT02088983 Not yet recruiting - Clinical trials for First Episode Schizophrenia

Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia

Start date: April 2014
Phase: Phase 2
Study type: Interventional

People with schizophrenia tend to have problems with attention and concentration. Studies found that these patients are unable to block or gate out non-relevant and distracting information (e.g., noises). This may lead to brain overload. Cognitive abilities like concentration, memory, and learning may worsen. This ability to filter sensory information has been linked to a gene that affects the way nicotine acts in the brain. Patients with schizophrenia have a high rate of cigarette smoking. 60% to 90% smoke compared with 25% of the general population. It has been suggested that these patients may use nicotine to improve their ability to block out distracting information. Brain wave activity (EEG) in response to sounds has been proved useful in understanding this gating problem. The present study uses EEG measures and performance tasks to find out what a new nicotine-like treatment, which will be added to ongoing treatment medications, does to gating and cognition. It is hoped that this new treatment will improve the way in which patients process information, as this may help them in day-to-day activities.